The August issue of U.S. magazine Site Selection features an article entitled The Phoenix of Québec: NEOMED brings instant pain relief to life sciences R&D in Greater Montréal , which brings to light the key role played by the NEOMED Institute in Québec’s life-sciences industry. The article also paints a complimentary picture of the research and cooperation potential for foreign companies interested in partnering with the Institute.
Adam Bruns, the magazine’s Managing Editor, conducted a series of interviews with such industry figures as Max Fehlmann, NEOMED’s President and Chief Executive Officer, and Philippe Walker, the Institute’s Chief Scientific Officer and former Head of AstraZeneca’s R&D centre in Montréal, as well as Dr. Helmut Thomas, President and CEO of Cyclenium Pharma, and Anthony Cheung, President and CEO of enGene.
This is Adam Bruns’ second article this year on Québec’s life-sciences industry. Last June, he published They Want Your Blood: Korea’s Green Cross makes a major investment in Québec , which discussed the opening of a blood plasma fractionation plant by Korean company Green Cross.
“[...] once you churn, Montréal is probably the best place in Canada.” says Anthony Cheung, President and CEO of Engene, a Vancouver-based pharmaceutical company that recently decided to set up operations at the NEOMED Institute. Site Selection, August 2014